Filing Overview
Sotera Health Company filed a Form 8-K dated February 23, 2023, reporting entry into a new first-lien credit agreement and related debt financing. The filing does not provide operating results for a quarterly or annual reporting period.
Material Financing Terms
- Facility: $500 million Term Loan B under a new First Lien Credit Agreement.
- Interest rate: At the company’s option, Term SOFR plus 3.75% or Base Rate plus 2.75%. Term SOFR has a 0.50% floor.
- Maturity: December 13, 2026.
- Amortization: 1% per year.
- Repricing protection: A 1.00% “soft call” premium applies to certain repricing transactions during the first six months after effectiveness.
- Security and guarantees: Obligations are guaranteed by Sotera Health Company and certain wholly owned material U.S. subsidiaries and secured by substantially all assets of the company, the borrower and guarantors, subject to customary exceptions.
- Covenants: The agreement includes customary representations, events of default and restrictions on indebtedness, liens, investments, fundamental changes, asset dispositions, dividends and other distributions.
Use of Proceeds and Liquidity
The company expects to use the Term Facility, together with cash on hand, to fund the proposed $408 million ethylene oxide litigation settlement in Cook County, Illinois, repay borrowings under its revolving credit facility, enhance liquidity and fund other general corporate purposes.
The settlement remains subject to specified conditions and limitations. The filing does not provide a post-transaction liquidity balance, revolving credit availability, leverage ratio, cash flow information or details regarding the amount of revolving debt to be repaid.
Changes Versus the Prior Period
- The company and Sotera Health Holdings, LLC entered into a new first-lien credit agreement on February 23, 2023.
- The transaction created a new $500 million secured Term Loan B facility and a related direct financial obligation.
- The filing does not present comparable-period revenue, earnings, margins or cash flow data.
Outlook, Risks and Unusual Items
- The financing is intended in part to support the proposed $408 million ethylene oxide litigation settlement.
- Completion of the settlement is conditional and subject to limitations described in the company’s January 9, 2023 Form 8-K.
- The new debt exposes the company to variable interest rates and requires repayment at maturity in December 2026, subject to the agreement’s terms.
- Collateral requirements, guarantees and restrictive covenants may limit financial and operating flexibility.
- The filing does not provide management guidance regarding revenue, profit, cash flow or leverage.
Investor Verification Items
- Verify the full Credit Agreement when filed as an exhibit to the company’s next Form 10-K, including covenant calculations, mandatory prepayments and events of default.
- Confirm whether the proposed $408 million settlement closes and identify the final funding sources and cash impact.
- Review subsequent filings for the amount of revolving debt repaid, remaining liquidity and total debt balances.
- Assess the impact of variable-rate borrowing and the December 2026 maturity on interest expense and refinancing risk.
- Review subsequent disclosures for any changes to the litigation settlement’s conditions, limitations or timing.